Drug Trial Radar · NCT06412224
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)
Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Dec 31, 2024
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Li XiaorongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Refreshgene Technology Co., Ltd.
- First posted
- May 14, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of RRG001 gene therapy after vitrectomy.
Conditions
- PDR - Proliferative Diabetic Retinopathy
Interventions
RRG001Drug
Administered by subretinal injection. Dosage form: injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the incidence of DLTs (dose limiting toxicity analysis) at most 6 subjctsTime frame: Within 28 days after RRG001 administration
- To evaluate the incidence of AEs(Adverse Event) as assessed CTCAE 5.0 at most 6 subjctsTime frame: Within 24 weeks after RRG001 administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin medical university eye hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.